HHealthcare Read More Obesity, M&A, Biotech Resurgence: A 2026 Guide to Health StocksJanuary 10, 2026 The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth…
HHealthcare Read More AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)January 9, 2026 Durham, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) — AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated…
MMedication Read More Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag DisorderJanuary 8, 2026 WASHINGTON, Jan. 8, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received…
FFitness Read More US FDA to limit regulation of health and fitness wearables, commissioner saysJanuary 8, 2026 By Puyaan Singh Jan 6 (Reuters) – The U.S. Food and Drug Administration said on Tuesday that it…
HHealthcare Read More BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®January 7, 2026 BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
MMedication Read More US FDA declines to approve Corcept’s drug for rare hormonal disorderJanuary 2, 2026 By Sneha S K and Sahil Pandey Dec 31 (Reuters) – The U.S. Food and Drug Administration has…
MMedication Read More Vanda Jumps 21% After FDA Approves Motion Sickness TherapyDecember 31, 2025 This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S.…
MMedication Read More Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with HypercortisolismDecember 31, 2025 REDWOOD CITY, Calif., December 31, 2025–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery…
MMedication Read More Aptar’s Bidose Nasal System Delivers CARDAMYSTâ„¢ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)December 19, 2025 Milestone Pharmaceuticals received U.S. Food and Drug Administration approval of CARDAMYST for the conversion of acute symptomatic episodes…
MMedication Read More FDA OKs libido-boosting pill for older women who have gone through menopauseDecember 15, 2025 WASHINGTON (AP) — U.S. health officials have expanded approval of a much-debated drug aimed at boosting female libido,…
HHealthcare Read More New blood tests for multiple cancers gain political backingDecember 5, 2025 Dec. 2 (UPI) — As a new blood tests capable of detecting dozens of cancers in their early…
MMedication Read More MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlowâ„¢ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney DiseaseDecember 2, 2025 MannKind If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under…